Cytokinetics Inc (CYTK)

10:18 AM

Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus

10:18 AM

09:05 AM

Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India

09:05 AM

Apr 18, 2025

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com

Apr 18, 2025

Apr 17, 2025

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo

Apr 17, 2025

Apr 17, 2025

10 Best High Short Interest Stocks to Buy Now - Insider Monkey

Apr 17, 2025

Apr 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 17, 2025

Apr 17, 2025

Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 16, 2025

Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia

Apr 16, 2025

Apr 16, 2025

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN

Apr 16, 2025

Apr 16, 2025

Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus

Apr 16, 2025

Apr 15, 2025

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com

Apr 15, 2025

Apr 15, 2025

JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada

Apr 15, 2025

Apr 15, 2025

Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView

Apr 15, 2025

Apr 15, 2025

BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus

Apr 15, 2025

Apr 15, 2025

Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance

Apr 15, 2025

Apr 14, 2025

Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus

Apr 14, 2025

Apr 11, 2025

Cytokinetics, IncorporatedCommon Stock (NQ: CYTK - FinancialContent

Apr 11, 2025

Apr 10, 2025

Cytokinetics CEO Robert Blum sells $183,850 in stock By Investing.com - Investing.com South Africa

Apr 10, 2025

Apr 10, 2025

Cytokinetics CEO Robert Blum sells $183,850 in stock - Investing.com Australia

Apr 10, 2025

Apr 10, 2025

Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN

Apr 10, 2025

Apr 10, 2025

JMP reiterates Cytokinetics stock with $78 target on HCM trial optimism - Investing.com Canada

Apr 10, 2025

Apr 10, 2025

Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire

Apr 10, 2025

Apr 10, 2025

Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics - Endpoints News

Apr 10, 2025

Apr 10, 2025

Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes - TipRanks

Apr 10, 2025

Apr 09, 2025

Cytokinetics stock plunges to 52-week low of $33.67 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Cytokinetics’ CK-4021586 improves cardiac function in HFpEF - BioWorld MedTech

Apr 09, 2025

Apr 09, 2025

Cytokinetics (NASDAQ:CYTK) Given "Buy" Rating at HC Wainwright - MarketBeat

Apr 09, 2025

Apr 08, 2025

Cytokinetics EVP sells $72,360 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

Cytokinetics EVP sells $72,360 in stock - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - Investing.com

Apr 08, 2025

Apr 07, 2025

Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health By Investing.com - Investing.com Canada

Apr 07, 2025

Apr 07, 2025

Cytokinetics CCO Andrew Callos sells $103k in stock By Investing.com - Investing.com India

Apr 07, 2025

Apr 07, 2025

Cytokinetics CCO Andrew Callos sells $103k in stock - Investing.com

Apr 07, 2025

Apr 07, 2025

Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health - Investing.com

Apr 07, 2025

Apr 05, 2025

Cytokinetics director Robert Harrington sells shares worth $17,743 By Investing.com - Investing.com South Africa

Apr 05, 2025

Apr 05, 2025

Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com Australia

Apr 05, 2025

Apr 04, 2025

H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 04, 2025

Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 03, 2025

Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 03, 2025

Cytokinetics stock holds $78 target from JMP amid trial results - Investing.com

Apr 03, 2025

Apr 03, 2025

CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus

Apr 03, 2025

Apr 02, 2025

Why These Two Biotech Stocks Just Diverged - Investor's Business Daily

Apr 02, 2025

Apr 02, 2025

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia

Apr 02, 2025

Apr 02, 2025

Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK

Apr 02, 2025

Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals

Apr 02, 2025

Apr 02, 2025

Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha

Apr 02, 2025

Apr 01, 2025

Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals

Apr 01, 2025

Mar 31, 2025

Cytokinetics CEO Makes Major Stock Move! - TipRanks

Mar 31, 2025

Mar 31, 2025

Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals

Mar 31, 2025

Mar 31, 2025

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025